Overall, our research supports the 15-gene SMS classification as a reliable prediction tool for identifying patients who may benefit from anti-PD-1 treatment in patients with EGFR/ALK-negative NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.